| 14.6 0.48 (3.4%) | 07-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.38 | 1-year : | 22.92 |
| Resists | First : | 17.45 | Second : | 19.62 |
| Pivot price | 15.81  |
|||
| Supports | First : | 13.93 | Second : | 11.58 |
| MAs | MA(5) : | 14.72 |
MA(20) : | 16.49 |
| MA(100) : | 12.66 |
MA(250) : | 14.24 |
|
| MACD | MACD : | -0.4 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 9.9 |
D(3) : | 10.8 |
| RSI | RSI(14): 42.2 |
|||
| 52-week | High : | 30.1 | Low : | 8.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CLPT ] has closed above bottom band by 24.4%. Bollinger Bands are 10% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.87 - 14.96 | 14.96 - 15.04 |
| Low: | 13.95 - 14.06 | 14.06 - 14.15 |
| Close: | 14.44 - 14.59 | 14.59 - 14.74 |
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Mon, 27 Jul 2026
Clearpoint Neuro Inc (CLPT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mon, 27 Jul 2026
BlackRock (CLPT holder) discloses 7.1% beneficial stake in ClearPoint Neuro - Stock Titan
Mon, 27 Jul 2026
CLPT|Clearpoint Neuro Inc|Price:14.813|Chg%:+0.693 - TradingKey
Mon, 27 Jul 2026
Clearpoint Neuro Inc (CLPT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tue, 21 Jul 2026
ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026 - ACCESS Newswire
Tue, 21 Jul 2026
ClearPoint Neuro Q2 review starts Aug. 3 at 4:30 p.m. ET - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 30 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 5.4 (%) |
| Held by Institutions | 50.5 (%) |
| Shares Short | 3,700 (K) |
| Shares Short P.Month | 4,920 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | -71.6 % |
| Operating Margin | -70 % |
| Return on Assets (ttm) | -25 % |
| Return on Equity (ttm) | -149.8 % |
| Qtrly Rev. Growth | 42.9 % |
| Gross Profit (p.s.) | 0.84 |
| Sales Per Share | 1.35 |
| EBITDA (p.s.) | -0.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -14.61 |
| PEG Ratio | 0.6 |
| Price to Book value | 23.17 |
| Price to Sales | 10.78 |
| Price to Cash Flow | -17.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|